The FDA won't appeal a decision to overturn the conviction of a salesmen who was found guilty of...
The FDA won't appeal a decision to overturn the conviction of a salesmen who was found guilty of marketing narcolepsy drug Xyrem for treating drowsiness and chronic fatigue, two conditions for which the medicine wasn't approved. A court quashed the conviction because it said FDA regulations violated free speech in a decision that could have wide ramifications for the agency's ability to regulate off-label drug marketing.
From other sites
at CNBC.com (Nov 8, 2012)
at CNBC.com (Jun 14, 2011)
at CNBC.com (May 31, 2011)
at CNBC.com (Dec 31, 1969)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs